Biopharmaceutical company
Appears in 1 story
Developer of MT027, an allogeneic CAR-T for intracranial solid tumors
The FDA cleared T-MAXIMUM's off-the-shelf CAR-T, MT027, for a Phase 2 trial in brain metastases from lung and breast cancer. It's the second Phase 2 clearance for the therapy, which targets the tumor protein B7-H3 and is delivered directly into the brain.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
